# Proteros biostructures

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proteros-biostructures

- Industry: Biotechnology
- Headquarters: Germany
- Website: www.proteros.com/
- Total disclosed funding: $7.4M
- Latest round: Series B (Aug 22, 2007)
- Investors on record: 1

## About

Founded in 2000 and based in Germany, Proteros biostructures GmbH specializing in early drug discovery, focusing on complex biologics and protein therapeutics through advanced structural biology techniques. Proteros biostructures GmbH provides early-stage drug discovery services, assisting pharmaceutical and biotechnology companies in understanding complex biologic targets. In February 2023, Inflexion Private Equity Partners acquired a minority stake in Proteros biostructures GmbH from BayBG.

Proteros specializes in early drug discovery services, focusing on the development of complex biologics and protein-based therapeutics. The company’s core offerings include elucidation of intricate protein structures, high-resolution protein crystallography, and cryo-electron microscopy (cryo-EM). Proteros assists clients in accessing challenging drug targets, including multi-subunit protein complexes and membrane-associated proteins, critical for innovative drug discovery. Their proprietary technology platform allows for customized assays, including binding, kinetics, and biochemical profiling, tailored to client needs. Their customer base encompasses pharmaceutical and biotechnology companies worldwide, with a notable presence in North America and Europe.Proteros operates within a business-to-business model, primarily serving pharmaceutical and biotech firms seeking advanced drug discovery solutions.

## Funding rounds

- Series B, Aug 22, 2007, $7.4M — BayBG

## Investors

- BayBG (https://capitalatlas.ai/funds/baybg) — Series B